NCT04943224View on ClinicalTrials.gov

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Histiocytosis
Interventions
DRUG

Trametinib

\< 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,

Trial Locations (1)

01-211

RECRUITING

Mother and Child Institute, Warsaw

All Listed Sponsors
collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

collaborator

Łukasiewicz Research Network

UNKNOWN

collaborator

Wrocław University of Environmental and Life Sciences

UNKNOWN

lead

Anna Raciborska

OTHER